Tracker

CDSCO approvals

CDSCO's list of new drug and clinical trial approvals holds 310 permission letters dated 2022, from January 4, 2022 to December 30, 2022. GCT is the most common kind of permission, with 94. Each row gives the company, product, kind of permission, date and a link to the letter, and CDSCO's file number where its text gives it.

From CDSCO's CT Approvals list, read . Each product links to CDSCO's PDF of its letter. The date is the one CDSCO gives on its list; the file number is printed in the letter. Not stated: file number on 2 rows. The file number is not read from 166 scanned letters: we read a letter's text, not its image.

The kinds of permission are CDSCO's own. FDC is fixed-dose combination (CDSCO's guidance for its Subject Expert Committees, page 13); GCT is global clinical trial (CDSCO's FAQs on the New Drugs and Clinical Trials Rules, page 8); IND is Investigational New Drug (CDSCO's guidance for its Subject Expert Committees, page 3); SND is Subsequent New Drugs (CDSCO's Citizen's Charter, page 2); rDNA is recombinant Deoxyribonucleic Acid (CDSCO's FAQs on the New Drugs and Clinical Trials Rules, page 3, which that page writes r-DNA).

December 2022

November 2022

October 2022

September 2022

August 2022

July 2022

June 2022

May 2022

April 2022

March 2022

February 2022

January 2022